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Background: Fatigue is common in cancer patients receiving adjuvant chemotherapy. To further understand the
mechanism of fatigue and search for potential biomarkers, we conducted this prospective study. Methods
We enrolled breast cancer (BC) patients before their first adjuvant Adriamycin-based chemotherapy cycle. Patients
responded to the brief fatigue inventory (BFI) and Chalder fatigue questionnaires and had their blood drawn for
both plasma evaluation and evaluation of the peripheral mononuclear cell fraction (PMNCF) mRNA expression of
various biomarkers. We evaluated FSH, LH, estradiol, DHEA, DHEAS, IL6, IL2, ILIRA, IL1β, CRP, Cortisol in the plasma
and IL2, IL10, IL6, TGF-β, KLRC1, TNF, BTP, SNCA, SOD1, BLNK, PTGS2 and INF γ expression in the PMNCF.
Results: 11 patients did not exhibit an increase in their BFI scores and served as controls, whereas 32 patients
exhibited an increase in their BFI scores compared with the baseline scores. From the biomarkers we evaluated in
the PMNCF, the only one significantly associated with fatigue was TGF-β (p = 0.0343), while there was a trend
towards significance with KLRC1 (p = 0.0627). We observed no evidence of significant associations of any plasma
biomarkers with the development of fatigue. However when we analyzed patients with more severe fatigue, plasma
IL1-RA levels correlated directly with higher fatigue scores (p = 0.0136).
Conclusions: We conclude that fatigue induced by chemotherapy in BC patients is associated with changes in IL1-ra
plasma levels and in TGF-β lymphocyte expression. Its mechanism may be different than that observed in long-term BC
survivors or that induced by radiation therapy.
Trial registration: NCT02041364 [ClinicalTrials.gov]
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Breast cancer is the most frequently diagnosed cancer
and the leading cause of cancer death among females,
accounting for 23% of total cancer cases and 14% of can-
cer deaths [1]. The use of adjuvant systemic therapy is
responsible, at least in part, for the reduction in cause-
specific mortality from breast cancer [2]. The decision to
use adjuvant chemotherapy for non-metastatic disease
takes into account tumor histology, expression of estro-
gen and progesterone receptors, amplification of human* Correspondence: felipemcruz@yahoo.com.br
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in any medium, provided the original work is pepidermal growth factor receptor 2 (HER 2), tumor size,
and nodal status [3].
The backbone of adjuvant chemotherapy treatment
consists of a regimen which contains taxanes and
anthracyclines and which is associated with the reduc-
tion in the risk of overall mortality when compared with
a regimen not using these drugs [4]. However, chemo-
therapy carries some side effects that may worsen a pa-
tient’s quality of life.
Cancer-related fatigue (CRF) is defined as a distres-
sing, persistent, subjective sense of physical, emotional,
and/or cognitive tiredness or exhaustion related to can-
cer or cancer treatment that is not proportional to re-
cent activity and differs from the normal fatigue thatOpen Access article distributed under the terms of the Creative Commons
g/licenses/by/4.0), which permits unrestricted use, distribution, and reproduction
roperly credited.
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and relieved by rest [5,6]. CRF is a very common symp-
tom in cancer patients at all stages of the disease’s evolu-
tion from its diagnosis and persists even to many years
after the end of the disease [6,7]. A majority of patients
will experience some level of fatigue during their course
of treatment and approximately one-third will have per-
sistent fatigue many years post-treatment [8,9]. However,
before assuming that fatigue is related to prior treatment
for breast cancer, treatable reasons for this symptom
should be ruled out, including anemia, thyroid dysfunc-
tion, pain, depression and lack of sleep.
The mechanisms responsible for this condition are
poorly understood. Major obstacles to defining the rele-
vant pathophysiology of this symptom include the inher-
ent subjectivity of fatigue, the difficulty in establishing
objective behavioral correlates and the wide variety of
conditions unrelated to cancer or its treatment that con-
tribute to fatigue [10]. Some pathophysiologic hypoth-
eses have been proposed for CRF causes such as
disrupted circadian rhythms [11], loss of muscle mass
[12], chronic stress response mediated through the
hypothalamic pituitary axis [12,13], systemic inflamma-
tory response [14-17] and pro-inflammatory cytokines
[18,19]. However, none of these hypotheses have been
proved yet.
The role of inflammatory cytokines may be based
upon several lines of evidence. Non-oncologic patients
with Chronic Fatigue Syndrome have increased levels of
pro-inflammatory cytokines such as IL1 beta, IL 1 recep-
tor antagonist and TNF-alpha [20,21], and fatigue is a
major side effect of cancer patients receiving interleu-
kins, TNF-alpha and interferon [22-24].
Patients with fatigue also present inflammatory changes
manifested by increased levels of several cytokines (IL1,
IL6) [20,25,26] and other inflammatory markers such as
the C-reactive protein (CRP) [27]. Indeed, tumor cells are
located in both the primary tumor and metastases in dir-
ect proximity to stromal cells such as lymphocytes and
macrophages which secrete various cytokines. In turn, the
proliferation of nearby tumor cells ADDIN BEC{Seruga
et al., [28], Nat Rev Cancer, 8, 887–99} may be positively
stimulated by this autocrine loop. These cytokines may
also contribute to the production of some of the more
common symptoms of widespread systemic cancer, for ex-
ample, fatigue and wasting [28]. Lanmark and colleagues
described alterations in the signaling pathways of B lym-
phocytes in patients with breast cancer with and without
fatigue [29]. More recently, cancer-related fatigue (CRF)
was associated to the over-expression of alpha-synuclein
(SNCA), which is present in diseases such as Parkinson’s
[30] and is involved in some cases of hereditary amyloid-
osis [31]. This may indicate the potential role of inflamma-
tory pathways in the development of CRF [32].Since patients undergoing adjuvant chemotherapy for
breast cancer often manifest fatigue [33], this scenario
can be considered as providing a true experimental
model for research of biomarkers of this symptom. The
identification of potential fatigue biomarkers may be
helpful to establish predictive markers of response to
therapy in chemotherapy induced fatigue trials. This
work explores the possibility of evaluating changes in
cytokine production observed both in the plasma and
mononuclear fraction of the peripheral blood of patients
with breast cancer and fatigue in order to ascertain if
there are specific patterns of cytokine expression that
may be identified in these patients.Methods
Clinical study
Patients with stage I, II and III breast cancer undergoing
adjuvant systemic chemotherapy based on the use of
anthracyclines were screened before the start of their
treatment. We excluded patients with any condition
which may cause fatigue such as hypothyroidism, per-
sonal history of self reported depression, anemia, de-
compensated heart failure or hypertension (systolic
pressure ≥ 140 mmHg and or diastolic pressure ≥ 90).
Our Institutional Ethics Committee approved this study.
Patients who agreed to participate by signing an in-
formed consent form received their first cycle of chemo-
therapy. Patients whose level of fatigue as measured by
the Brief Fatigue Inventory (BFI) increased by at least
one point after having received the first cycle of chemo-
therapy were considered as having manifested fatigue in-
duced by chemotherapy.
The patients whose fatigue did not worsen following the
first cycle of chemotherapy served as controls.
The patients completed questionnaires to evaluate their
fatigue (BFI [34] and Chalder [35]) and had blood drawn
before the start of chemotherapy and before the second
cycle of chemotherapy. The two questionnaires had previ-
ously been validated for use in Portuguese [36,37].
We chose, based on a literature review, the following
biomarkers to be evaluated in the serum as well as their
expression in peripheral blood mononuclear cells: IL-2,
IL-10, SOD1, BLNK, PTG S2, KLRC1, TGB1, IL 6,
IFNG, TNF, SNCA, BTP.
Analysis of gene expression
RNA extraction
We reviewed the relevant literature to select potential
plasma biomarkers and genes whose expression in
lymphocytes could relate to the process of fatigue pro-
duced by chemotherapy. Blood samples were collected
Upon venous puncture. Tubes containing EDTA for
RNA extraction were collected. The total RNA of the
Table 1 Characteristics of the specific primers used to
validate the gene expression results
Gene Sequence (5’ - 3’) Amplicon
(bp)
No. access
IL2 F-CCCAAGAAGGCCACAGAACT 125 NM_000586.3
R-TTGCTGATTAAGTCCCTGGGT
IL10 F-GCTGAGAACCAAGACCCAGA 141 NM_000572.2
R-ATTCTTCACCTGCTCCACGG
SOD1 F- GGTGGGCCAAAGGATGAAGA 129 NM_000454.4
R- GCCAATGATGCAATGGTCTCC
BLNK F- AACAGGAAGCTGGCGTTCTC 124 NM_013314.3
Cruz et al. Clinical and Translational Medicine  (2015) 4:4 Page 3 of 9patients included in this study was extracted from the
mononuclear fraction of peripheral blood (MFPB)
using the QIAamp RNA Blood Mini Kit (Qiagen, cat.
no. 52304). The mass and purity of RNA were deter-
mined by spectrophotometry at wavelength from 260
to 280 nm. Samples with a 260/280 ratio between 1.8
and 2.0 were considered valid. To exclude trace
gDNA, the RNA samples were treated with DNase I
Amplification Grade (Invitrogen, catalog No. 18068–
015), according to the manufacturer’s protocol. The
total RNA of the samples was stored at −80°C until
conversion into cDNA.R- TGGCCAGAGCTTTTCCGAAT
PTGS2 F- TGAGTGTGGGATTTGACCAGT 128 NM_000963.2
R- GTGCACTGTGTTTGGAGTGG
KLRC1 F- ACCATCCTCATGGATTGGTGT 163 NM_002259.4
R- TGAAGATCCACACTGGGCTG
TGB1 F-CTGACTGCTCTGGCTTCCTC 176 NM_002704.3
R- TGGGTTCCTTTCCCGATCAC






TNF F- AGAGGGAAGAGTTCCCCAGG 123 NM_000594.3
R- CCTCAGCTTGAGGGTTTGCT
SNCA F- ATGTTGGAGGAGCAGTGGTG 134 NM_000345.3
R- CTGTGGGGCTCCTTCTTCAT
BTP F- CAGCACCTACTCCGTGTCAG 142 NM_000954.5
R-CTTTAACTCAGCCCTGGGGGCDNA synthesis
CDNA was synthesized from 500 ng of total RNA using
the SuperScript III First-Strand Synthesis SuperMix for
qRT-PCR kit (Invitrogen, Cat. no. 11752–250).
Amplification reaction
The Δ amplification reactions using hydrolysis probes
present in the customized plates were performed in a
7500 thermocycler (Applied Biosystems) in a final vol-
ume of 20 μL containing 1X TaqMan Master Mix
(Applied Biosystems, PN4391016) and 2.0 μL of cDNA
diluted 10X. The thermal cycling conditions used were
an initial step of 2 min at 50°C and 10 min at 95°C
followed by 40 cycles of 15 sec at 95°C and 1 min at 60°C.
Gene expression was evaluated using the standard curve
method.
Amplification reactions of 12 differentially expressed
genes identified between the constants on the plates
with a hydrolysis probe were performed for 45 patients
using the SYBR Green system (QuantiFast SYBR Green
PCR Kit, Qiagen, Cat no. 204057). The amplification re-
actions occurred in a final volume of 15 μL containing
1X SYBR Green buffer, 0.25 μM primers (for IL2, IL10,
SOD1, BLNK and PTGS2 genes) or 0.20 μM primer (for
KLRC1, TGB1, IL6, IFNG, TNF, SNCA and BTP genes)
and 2.0 μL of 10X diluted cDNA. The thermal profile
used was an initial step of 95°C for 10 minutes and 40 cycles
of 95°C for 15 seconds and 60°C for 60 seconds (for IL2,
IL10, SOD1, BLNK and PTGS2 markers) and an initial
step of 95°C for 10 minutes and 40 cycles of 95°C for
15 seconds and 61°C for 60 seconds for the remaining
markers.
Specific primers for validation: the specific primers for
each target gene in this study were designed using the
Primer-Blast tool, available at http://www.ncbi.nlm.nih.
gov/tools/primer-blast/index.cgi?LINK_LOC=BlastHome
(Table 1).
QPCR results analysis: The results of gene expression
obtained with hydrolysis probe plates were analyzed
using the standard curve method, and the geneexpression results in the validation phase were obtained
using the formula 2-ΔCq.
Plasma dosages
Blood samples were collected by peripheral venipuncture.
Approximately 12.0 mL of whole blood was collected from
each patient at the times proposed in the clinical protocol.
After collection, the samples were centrifuged, and the
plasma was obtained for determination of hormones and
interleukins. The FSH, LH, estradiol, DHEA, DHEAS and
cortisol hormones were determined by chemiluminescent
enzyme immunometric assay using an Immulite 1000
luminometer. The IL6, IL2 and usCRP cytokines were de-
termined by competitive enzyme assay and also from a
chemiluminescent reading using an Immulite 1000 lumin-
ometer. The remaining components, such as ILIRA and
IL1β, were determined by enzyme immunoassay and an
optical density reading using a Labotech ELISA semi-
automated reader. All the determinations were evaluated
in duplicate following best practice in clinical analysis.
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We evaluated comparisions between continuous vari-
ables and categorical variables using the Kruskal-Wallis
test when a continuous variable distribution was not
normal and we employed the ANOVA test if its distri-
butions was normal. The normality of the distribution
of continuous variables was evaluated using the
Kolmogorov-Smirnov test. P values of less than 0.05
were considered significant. The Prism® program ver-
sion 6d (GraphPad Software, La Jolla California USA,
www.graphpad.com) was used to perform all the statis-
tical calculations in this study.
Results
A total of 43 female patients were included. The BFI
questionnaire fatigue score of 11 of these patients did
not increase, and they were therefore considered as con-
trols. Patients whose BFI score increased at least 1 pointTable 2 Clinical characteristics of recruited patients
Patients with fatigue








Body Mass Index 23.1 ± 2
Histological Type
Ductal Carcinoma 28 (87.4%)
Lobular Carcinoma 2 (6.3%)
Metaplastic Carcinoma 2 (6.3%)
Hormone Receptors/HER2
Hormone Receptor - positive, HER2 -positive 9 (28.1%)
Hormone Receptor - positive, HER2 - negative 13 (40.7%)






Lack of Comorbidities 26 (81.3%)
Arterial hypertension 2 (6.2%)
Diabetes mellitus 4 (12.5%)
Menopausal Status
Premenopausal 13 (40.6%)
Postmenopausal 19 (59.4%)after the first cycle of chemotherapy constituted the
fatigue group (n = 32).
We observed a statistically significant difference be-
tween the BFI global scores of the fatigue group and
those of the control group(Mean BFI Fatigue = 44,2
range: 4–89 vs. Mean BFI control = 0,9, range 0–2,
p = 0,0001). The classifications of the severity of fatigue
by Chalder and BFI were similar. The clinical character-
istics of the patients are shown in Table 2.
Evaluation of plasma level and biomarker lymphocyte
expression in patients before and after chemotherapy
who developed or did not develop fatigue
Figure 1 reveals the significant variations of fatigue in
each group being evaluated in Figures 2 and 3, which in
turn illustrate the changes observed in the biomarkers
evaluated in the blood and lymphocytes, respectively, for
all the study patients.(randomized) Patients without fatigue (control) p
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Figure 1 The significant variations in fatigue in the 3 groups
evaluated in Figures 2 and 3, namely patients at the screening
stage (inclusion, all patients), including all 43 patients (32
patients whose fatigue worsened after chemotherapy and 11
patients whose fatigue did not worsen after chemotherapy and
who served as controls for this stage of data analysis). The
black dots represent the outliers.
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served in the plasma (Figure 2). We did however observe
a significant variation in the lymphocyte expression of
TGFB1 in these groups and a trend toward significance
for the expression of KLRC1 (p = 0.06) and BTP (p = 0.09).
As an exploratory analysis, we stratified patients by
the increase in their BFI scores in two groups: 1) who
had more severe fatigue (ie had at least one Standard
deviation (SD) increase in their BFI scores after the first
cycle of chemotherapy) and 2) those who had lower
increases in their BFI scores. We observed then a posi-
tive association with ILI-ra (p = 0.0136) and with TGF-β
(p = 0.0505). Interestingly TGF-β levels were higher in
less severe fatigued patients (Figure 4).
Discussion
We observed no plasma biomarker in our study that was
statistically significantly associated with the presence of
chemotherapy-induced fatigue. However, in an explora-
tory analysis of patients who were more fatigued, weidentified plasma IL1-ra as a potential biomarker of
chemotherapy induced fatigue. Interestingly, when
evaluating the lymphocyte expression of several potential
markers, we observed a significant correlation between
fatigue and expression levels of TGFB-1 and a trend for
KLRC1 and BTP.
The TGFB-1 gene, also known as PPBP, encodes a pro-
tein that is a platelet derived growth factor and exhibits
intense chemotactic activity for neutrophils and stimu-
lates DNA, glycolysis, mitosis, cAMP intracellular accu-
mulation and prostaglandin E2 synthesis, among other
activities. Among our patients, we observed that those
who developed fatigue after the first cycle of chemother-
apy exhibited higher levels of this gene than the patients
who did not develop fatigue. Kennedy and colleagues
also observed high levels of TGFB-1 in the peripheral
blood of patients with chronic fatigue which was associ-
ated with an increased rate of neutrophil apoptosis when
compared with controls without chronic fatigue [38].
Interestingly in our exploratory analysis, unlike IL1-ra,
TGFB-1 seems to be associated with less severe degrees
of fatigue.
The KLRC1 gene encodes a protein expressed in NK
cells and, in association with KLRD1/CD94, this protein
is involved in the recognition of HLA class I molecules
by NK cells. NK cells play an important role in the im-
mune system and in the immune response to tumors.
Aspler [39], who studied gene expression of peripheral
blood cells of patients with chronic fatigue, also
described a negative association between chronic fatigue
and the presence of genes expressed in NK cells. In our
study, patients who did not exhibit fatigue after the first
cycle tended to express less KLRC1 than at the screening
stage.
The BTP gene encodes a protein known as beta-trace
protein (BTP) or PTGDS that is homologous to the
glutathione-independent prostaglandin synthetase en-
zyme that catalyzes the conversion of prostaglandin H2
to prostaglandin D2 (PGD2). PGD2 acts as a neuromo-
dulator and a trophic factor in the central nervous sys-
tem. In addition to these functions, PGD2 is also
important for smooth muscle contraction and is an im-
portant inhibitor of BTP platelet aggregation (PTGDS)
that may also be involved in the regulation of non-
REM sleep [40]. In our study, we observed that patients
without fatigue after the first cycle of chemotherapy
had a tendency to exhibit increased levels of BTP
(PTGDS), suggesting that higher levels of this substance
could be associated with protection from fatigue.
The significant positive association between higher fa-
tigue scores and IL-1ra that we found in an exploratory
analysis has also been reported by others [17,18,41,42].
This association, however, appears to be counterintuitive
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Figure 2 Evaluation of plasma analytes in patients in the inclusion phase whose fatigue worsened and in patients whose fatigue did
not worsen after the first cycle of chemotherapy (controls). The black dots represent the outliers.
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without agonist activity it would be expected to have an
anti-inflammatory action. Whether the increase in IL1-
ra that we observed was a reaction to even more in-
creased IL1-β levels (which we were unable to document
in this study) or to high levels of other IL-1 family mem-
bers is unknown [32].
While this study was conducted in a prospective
manner with multiple biomarkers, several other issues
should be considered in interpreting the results. Pri-
marily, the results are not generalizable to all cancer
patients with fatigue. In addition, a limitation of our
study is that it consisted of only a small sample of
breast cancer patients receiving Adriamycin-based
chemotherapy. It is possible that other chemotherapy
regimens or cancer of other sites could have different
biomarker profiles than that which we observed. Thenumber of controls who did not experience fatigue was
also limited. Because fatigue is extremely prevalent in
cancer patients receiving chemotherapy, controls who
did not have an increase in fatigue scores after the first
cycle of chemotherapy were few. This small number of
controls consisting of only 11 patients may have under-
powered our study to detect potential smaller, albeit
significant biomarker differences, between fatigued and
non-fatigued patients.
The aim of our study was to evaluate potential bio-
markers of chemotherapy induced fatigue. That is the
reason we used cancer patients without an increase in
their fatigue global scores after having received chemo-
therapy as controls. We divided our patients in two
groups, those who developed fatigue and those who did
not (the controls) after the first cycle of chemotherapy,
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Figure 3 Evaluation of lymphocyte expression of selected genes in the first phase of the study in patients in the inclusion phase
whose fatigue deteriorated and in patients whose fatigue did not worsen after the first cycle of chemotherapy (controls). The black
dots represent the outliers.
Cruz et al. Clinical and Translational Medicine  (2015) 4:4 Page 7 of 9identify potential biomarkers of fatigue. In order to
exclude spurious findings due to the inclusion in the fa-
tigue group of patients with very modest increases in
their BFI scores, we also evaluated separately the group
of patients who had the largest increases in their BFI
scores and compared them with the controls. In fact, the



























T FLSF FH T SF
Figure 4 Patients who developed fatigue where separated in two gro
increase equal or above 1 standard deviation (20 points) in their BFI
lower increases in their BFI scores (FL). Also shown are those patients w
chemotherapy who were considered as controls (C).allowed us to identify biomarkers which will need to be
validated in the future in a larger sample of patients.
Fatigue linked to chemotherapy appears to play a
minor role in the hypothalamic pituitary axis and even
in several inflammatory cytokines such as IL-6, IL-1, IL2
as described in other studies [32,43,44]. It is possible
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ups: those who had higher BFI fatigue scores (HF), ie who had an
scores as compared to the triage (T) level and 2) those who had
ho had a decrease in their BFI scores after the first cycle of
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cancer months or years after treatment [17,29]. We
believe that further studies, focused on this patient
population and with a broader panel of biomarkers, may
be capable of unraveling possible mechanisms for the
genesis of this symptom and validate our findings.Conclusions
We conclude that fatigue induced by chemotherapy in
BC patients is associated with changes in IL1-ra plasma
levels and in TGF-β lymphocyte expression. Its mechan-
ism may be different than that observed in long-term
BC survivors or that induced by radiation therapy.
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